Publication:
Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders

Placeholder

Organizational Units

Program

Authors

Kocaman, Gulsen
Kahraman, Nese
Gurkan Koseoglu, Banu
Matur, Zeliha
Ertas, Mustafa
Gulsen, Yesim
Baykan Baykal, Betul

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD.

Description

Source:

Keywords:

Keywords

Citation

Kocaman G., Kahraman N., Gurkan Koseoglu B., Bilgic B., Matur Z., Ertas M., Gulsen Y., Baykan Baykal B., -Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders-, NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.55, ss.330-336, 2018

Endorsement

Review

Supplemented By

Referenced By

3

Views

0

Downloads

View PlumX Details


Sustainable Development Goals